PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1743369
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1743369
Breakthrough Therapy Designation Market Growth, Size, Trends Analysis - By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Breakthrough Therapy Designation Market Introduction and Overview
According to SPER market research, 'Global Breakthrough Therapy Designation Market Size- By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Breakthrough Therapy Designation Market is predicted to reach 431.11 billion by 2034 with a CAGR of 14.48%.
The FDA's Breakthrough Therapy Designation program is intended to speed up the development and evaluation of medications for serious or life-threatening illnesses. The medicine must provide a significant improvement over current therapy on important endpoints, according to preliminary clinical evidence, in order to qualify. Rolling review, extensive FDA advice, and possible priority review for clearance are some advantages of this category.
Restraints: A major obstacle to receiving Breakthrough Therapy (BT) classification is high development costs, since BT frequently necessitates enormous resources, cutting-edge technologies, and long clinical studies. Smaller pharmaceutical companies may find it difficult to compete with larger players in the market due to the financial burden these charges might cause. This financial strain may potentially impede the expansion of the market by delaying the research and approval of treatments.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered By Application, By End User
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
- F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer, Inc, AbbVie, Inc, Bristol-Myers Squibb Company, Gilead Sciences, Inc, Sanofi, Regeneron Pharmaceuticals Inc, AstraZeneca, Boehringer Ingelheim GmbH.
Global Breakthrough Therapy Designation Market Segmentation:
By Application: Based on the Application, GlobalBreakthrough Therapy Designation Market is segmented as; Oncology, InfectiousDiseases, Rare Diseases, Autoimmune Diseases, Pulmonary Diseases, NeurologicalDisorders.
By End User: Based on the End User, GlobalBreakthrough Therapy Designation Market is segmented as; Hospitals, Clinics,Research Institutes, Laboratories.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East& Africa.
Table of Contents
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER's internal database
2.1.4. Premium insight from KOL's
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER's Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Breakthrough Therapy Designation Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Breakthrough Therapy Designation Market
7. Global Breakthrough Therapy Designation Market, By Application 2021-2034 (USD Million)
7.1. Oncology
7.2. Infectious Diseases
7.3. Rare Diseases
7.4. Autoimmune Diseases
7.5. Pulmonary Diseases
7.6. Neurological Disorders
8. Global Breakthrough Therapy Designation Market, By End User 2021-2034 (USD Million)
8.1. Hospitals
8.2. Clinics
8.3. Research Institutes
8.4. Laboratories
9. Global Breakthrough Therapy Designation Market, 2021-2034 (USD Million)
9.1. Global Breakthrough Therapy Designation Market Size and Market Share
10. Global Breakthrough Therapy Designation Market, By Region, 2021-2034 (USD Million)
10.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
10.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. AbbiVie, Inc.
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. AstraZeneca
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Boehringer Ingelheim International GmbH.
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Bristol-Myers Squibb Company
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. F. Hoffmann-La Roche Ltd.
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Gilead Sciences, Inc.
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Novartis AG
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Pfizer, Inc.
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Regeneron Pharmaceuticals Inc.
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Sanofi
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links
